{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:21:52Z","timestamp":1788898912592,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.semradonc.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T19:35:43Z","timestamp":1622662543000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC"],"prefix":"10.1016","volume":"31","author":[{"given":"Sean","family":"All","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Garant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2021.02.002_bib0001","unstructured":"Institute NC. Cancer stat facts: kidney and renal pelvis cancer. 2020; https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Accessed September 22, 2020."},{"key":"10.1016\/j.semradonc.2021.02.002_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q","article-title":"Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: A Swiss experience with 588 tumors","volume":"89","author":"Moch","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0003","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0005","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: A population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: A population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0009","unstructured":"Network NCC. Kidney Cancer (Version 1.2021). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed October 4, 2020."},{"key":"10.1016\/j.semradonc.2021.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2021.02.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0012","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0013","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semradonc.2005.12.003","article-title":"Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases","volume":"16","author":"Kavanagh","year":"2006","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0014","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","article-title":"Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study","volume":"83","author":"Milano","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0015","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/cncr.26611","article-title":"Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease","volume":"118","author":"Salama","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0016","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nrurol.2011.30","article-title":"The role of metastasectomy in metastatic renal cell carcinoma","volume":"8","author":"Staehler","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000019849","article-title":"Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis","volume":"35","author":"van der Poel","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0018","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.25836","article-title":"Survival after complete surgical resection of multiple metastases from renal cell carcinoma","volume":"117","author":"Alt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","article-title":"Stereotactic body radiation therapy: A novel treatment modality","volume":"7","author":"Lo","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2006.09.7469","article-title":"Stereotactic body radiation therapy in multiple organ sites","volume":"25","author":"Timmerman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0021","first-page":"255","article-title":"Stereotactic body radiation therapy (SBRT) for genitourinary malignancies","volume":"10","author":"Teh","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0023","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.euo.2020.01.001","article-title":"Synchronous versus metachronous metastatic disease: Impact of time to metastasis on patient outcome-results from the international metastatic renal cell carcinoma database consortium","volume":"3","author":"Donskov","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0024","doi-asserted-by":"crossref","first-page":"78825","DOI":"10.18632\/oncotarget.20230","article-title":"Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.134564","article-title":"Pancreatic tropism of metastatic renal cell carcinoma","volume":"5","author":"Singla","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: A prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0028","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: A systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0029","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical metastasectomy in renal cell carcinoma: A systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eururo.2017.03.005","article-title":"Complications after metastasectomy for renal cell carcinoma-a population-based assessment","volume":"72","author":"Meyer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0031","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.euo.2019.08.011","article-title":"Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: Results from the phase 2 randomized open-label resort study","volume":"2","author":"Procopio","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0032","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","article-title":"Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model","volume":"50","author":"Walsh","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0033","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0034","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/spi.2005.3.4.0288","article-title":"Stereotactic radiosurgery for spinal metastases from renal cell carcinoma","volume":"3","author":"Gerszten","year":"2005","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wers\u00e4ll","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0036","first-page":"e6","article-title":"The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT)","volume":"3","author":"Teh","year":"2007","journal-title":"Biomed Imaging Intervent J"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0037","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2009.03.062","article-title":"Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy","volume":"76","author":"Nguyen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0038","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3171\/2012.8.SPINE12303","article-title":"Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma","volume":"17","author":"Balagamwala","year":"2012","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0039","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","article-title":"Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma","volume":"82","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/COC.0b013e31825d52b2","article-title":"Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma","volume":"36","author":"Ranck","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0041","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.21037\/jtd.2017.10.108","article-title":"Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group \"Stereotactic Radiotherapy\"","volume":"9","author":"Hoerner-Rieber","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0042","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0043","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0044","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.radonc.2018.04.028","article-title":"Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014","volume":"127","author":"Stenman","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.juro.2018.08.049","article-title":"Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma","volume":"201","author":"Franzese","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0046","article-title":"Treatment outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study","volume":"22","author":"Buti","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"10.1016\/j.semradonc.2021.02.002_bib0047","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","article-title":"Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review","volume":"54","author":"Kothari","year":"2015","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0048","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.clgc.2018.11.006","article-title":"Stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma","volume":"17","author":"Wardak","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0049","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s007010050139","article-title":"Gamma-knife radiosurgery for brain metastases of renal cell carcinoma: Results in 23 patients","volume":"140","author":"Sch\u00f6ggl","year":"1998","journal-title":"Acta Neurochirurgica"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0050","first-page":"372","article-title":"Brain metastases in renal cell carcinoma: Management with gamma knife radiosurgery","volume":"6","author":"Amendola","year":"2000","journal-title":"Cancer J"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0051","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0360-3016(00)00536-8","article-title":"The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma","volume":"47","author":"Goyal","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0052","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0360-3016(00)00804-X","article-title":"Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma","volume":"48","author":"Ikushima","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0053","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/jns.2000.92.5.0760","article-title":"Gamma surgery for intracranial metastases from renal cell carcinoma","volume":"92","author":"Payne","year":"2000","journal-title":"J Neurosurg"},{"issue":"5 suppl","key":"10.1016\/j.semradonc.2021.02.002_bib0054","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3171\/jns.2002.97.supplement_5.0489","article-title":"Gamma knife radiosurgery for renal cell carcinoma brain metastases","volume":"97","author":"Hernandez","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1442-2042.2002.00531.x","article-title":"Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: Results in 42 patients","volume":"9","author":"Hoshi","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0056","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2004-818511","article-title":"Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma","volume":"47","author":"Muacevic","year":"2004","journal-title":"Minim Invasive Neurosurg"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0057","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1078-1439(03)00104-2","article-title":"LINAC radiosurgery for brain metastasis of renal cell carcinoma","volume":"22","author":"Noel","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0058","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/cncr.23857","article-title":"Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery","volume":"113","author":"Samlowski","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0059","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00066-010-2055-z","article-title":"Radiotherapy for brain metastases from renal cell cancer: Should whole-brain radiotherapy be added to stereotactic radiosurgery?: Analysis of 88 patients","volume":"186","author":"Fokas","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11060-010-0170-4","article-title":"Treatment strategy for metastatic brain tumors from renal cell carcinoma: Selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema","volume":"98","author":"Shuto","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0061","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1227\/NEU.0b013e31822b2fdc","article-title":"Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases","volume":"69","author":"Kano","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0062","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ijrobp.2011.03.044","article-title":"Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival","volume":"82","author":"Kim","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0063","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1016\/j.wneu.2017.10.011","article-title":"Radiosurgery for treatment of renal cell metastases to spine: A systematic review of the literature","volume":"109","author":"Smith","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0064","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2019.01.072","article-title":"A phase 2 clinical trial of SABR followed by immediate vertebroplasty for spine metastases","volume":"104","author":"Wardak","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2021.02.002_bib0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3171\/2015.10.SPINE141261","article-title":"Vertebral compression fractures after stereotactic body radiation therapy: A large, multi-institutional, multinational evaluation","volume":"24","author":"Jawad","year":"2016","journal-title":"J Neurosurg Spine"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429621000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429621000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:52:32Z","timestamp":1760950352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429621000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1053429621000102"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2021.02.002","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}